Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502. The US, nine member countries of the Eurasian Patent Organisation, and two additional countries have already granted this patent.
Cleveland has filed 13 sets of patent applications in the US and internationally, related to Protectan technology around various aspects and properties for CBLB502 and related Protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.
Yakov Kogan, chief operating officer of Cleveland, said: “The continued extension of our patent coverage for CBLB502 in key geographies around the world is a testament to its completely unique approach to protection of healthy tissues from the impact of radiation and other acute stresses. We are particularly excited by this decision from the EPO, as it enables us to receive patents in up to 38 of its member countries, including every major European market.”